# CICC Jiacheng Investment Management

> CICC Jiacheng Investment Management is a VC fund in Beijing backing Manufacturing and Health Care. See 10 investments, check sizes, portfolio. Updated Aug 2026.

- Type: VC Fund
- Location: Beijing, China
- Total investments: 10
- Last investment: Jan 2024
- Lead investor: 20%
- Last updated: Aug 2026

CICC Jiacheng Investment Management is an Investment firm.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Manufacturing | 4 | 40% |
| Health Care | 3 | 30% |
| Biotechnology | 3 | 30% |
| Medical | 2 | 20% |
| Software | 2 | 20% |

23 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series C | 4 | 40% |
| Series D | 4 | 40% |
| Series B | 2 | 20% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Advanced Materials Technology & Engineering | Advanced Materials Tech& Eng is a semiconductor equipment manufacturer that focuses on the development of front-end process equipment, compound semiconductors and MEMS. | $70.4M | Series D | Jan 29, 2024 |  |
| Yingsheng Biology | Yingsheng Biotechnology Co., Ltd. (referred to as Yingsheng Bio) was established in 2009, and is committed to the application of molecular diagnostic techniques such as maternal and child health, neonatal genetic diseases, metabolic diseases, birth defects and other human genetics, and national eugenics engineering. Yingsheng's product lineincludes 45 innovative genetic metabolic disease screening reagents, 14 vitamins determination reagents, mass spectrometer automatic intelligent processing platform, and ultra-high performance liquid chromatography tandem mass spectrometry detection system. level. |  | Series C | Mar 29, 2022 |  |
| Creech Medical Technology Development | Creativity (Beijing) Medical Technology Development Co., Ltd. is a leading minimally invasive interventional delivery system product full solution provider. Committed to cooperating with top experts at home and abroad in the field of minimally invasive intervention, and cooperating with internationally renowned raw material manufacturers to jointlydevelop, produce and sell leading products. Provide doctors with differentiated diagnosis and treatment tools, relieve patients' pain and reduce medical burden. |  | Series D | Dec 22, 2021 |  |
| Horizon Robotics | Horizon Robotics is a leading provider of ADAS and AD solutions for passenger vehicles with proprietary software and hardware. Our solutions combine cutting-edge algorithms, purpose-built software and state-of-the-art processing hardware, providing the core technologies for assisted and autonomous driving that enhance the safety and experience ofdrivers and passengers. | $600M | Series C | Jun 10, 2021 |  |
| WT Microtech Medical | WT Microtech Medical mainly engaged in the R&D, production, sales and maintenance of the third category of medical devices. | $81.5M | Series D | Dec 28, 2020 |  |
| Microtech Medical | MicroTech Medical founded in January, 2011 in Hangzhou Future Technical City, which is the Industrial Garden for High-level Overseas Talents in Zhejiang Province, recieved capital from Eli Lilly and Company. They devote to innovate and manufacture high-tech and more affordable medical devices related to Diabetes Care. | $88M | Series D | Dec 28, 2020 |  |
| Paraview Software | Paraview Software is an enterprise-level IT management platform solution provider with ParaSecure OSC operation and maintenance security management software and ParaSecure AAC security log management system software. | $44.1M | Series C | Sep 23, 2020 |  |
| Thousand Oaks Biopharmaceuticals | Thousand Oaks Biopharmaceuticals is a developer of biopharmaceutical technologies intended to produce protein and vaccine compounds. The company's technologies provide integrated control solutions, including the use of technical expertise to optimize the process and increase protein expression to reduce production scale, providingbio-pharmaceutical companies with personalized, chemical-defined cell culture media, formula production, technical support and ancillary services. |  | Series B | Jul 24, 2020 |  |
| Yihang.ai | Yihang.ai manufactures autonomous driving systems. Yihang Intelligent provides the host factory with a complete auto-driving solution with high reliability, high quality and low cost. Since its establishment, Yihang Intelligent has been aiming at productization and strictly follows the development process of the main engine factory. At present,Autopilot has been commercialized, and Autopilot function autopilot solution is provided for a certain production model. It is applied to Level 4 deep learning technology research and development. Breakthroughs have also been made to achieve real-time pixel-level image segmentation based on deep learning on a car-level embedded chip. Yihang intelligent team is proficient in artificial intelligence and core algorithms such as sensing, decision-making, control and fault diagnosis. It integrates the elites of the automotive industry and experts in computer vision and deep learning. The team members are from domestic and foreign OEMs, Tier 1 suppliers, domestic and foreign. Leading scientific research institutions and famous universities at home and abroad such as Berkeley and Cambridge.It began operation in 2015, with its headquarters in Beijing in China. | $31.2M | Series B | Aug 29, 2018 |  |
| Unisound | Beijing Yunzhisheng Information Technology Co., Ltd. (云知声语音云) is a Chinese mobile internet startup focused on intelligent voice and speech processing technologies. Founded in June 2012, the company owns the speech recognition technologies with intellectually independent property rights. With the help of a cloud computing platform and mobileinternet technologies, it has launched a series of middleware and cloud platforms for speech recognition services, which provides internet enterprises and users with professional speech recognition services. Yunzhisheng’s core technology team is made up of people from domestically and internationally well-known enterprises, universities, and research institutes, of which above 80% own a doctoral degree along with more than 10 years of experience in the R&D of applications in voice recognition. | $85M | Series C | Jul 19, 2018 |  |

10 of 10 investments shown.

## Co-investors
- [CD Capital](https://shizune.co/investors/profile/cd-capital) — VC Fund, 3 deals together
- [Everbright](https://shizune.co/investors/profile/everbright) — VC Fund, 2 deals together
- Guofang Ziben — VC Fund, 2 deals together
- [IDG Capital](https://shizune.co/investors/profile/idg-capital-partners) — VC Fund, 2 deals together
- [Lilly Asia Ventures](https://shizune.co/investors/profile/lilly-asia-ventures) — VC Fund, 2 deals together
- [Qiming Venture Partners](https://shizune.co/investors/profile/qiming-venture-partners) — VC Fund, 2 deals together

## Similar investors

### Similar stage
- [Sequoia Capital](https://shizune.co/investors/profile/sequoia-capital) — VC Fund
- [New Enterprise Associates](https://shizune.co/investors/profile/new-enterprise-associates) — VC Fund
- [Bessemer Venture Partners](https://shizune.co/investors/profile/bessemer-venture-partners) — VC Fund

## FAQ

### What does CICC Jiacheng Investment Management invest in?

CICC Jiacheng Investment Management invests primarily in Manufacturing, Health Care and Biotechnology startups, most often at Series C and Series D stage. Most of the 10 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did CICC Jiacheng Investment Management last invest?

The most recent investment recorded for CICC Jiacheng Investment Management closed in Jan 2024. Shizune tracks 10 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co